Several analysts have recently updated their ratings and price targets for Rigel Pharmaceuticals (NASDAQ: RIGL):

  • 10/4/2017 – Rigel Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company’s pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel’s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. “
  • 10/4/2017 – Rigel Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $5.00 price target on the stock.
  • 10/2/2017 – Rigel Pharmaceuticals was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 10/2/2017 – Rigel Pharmaceuticals had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $5.00 price target on the stock.
  • 9/20/2017 – Rigel Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company’s pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel’s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. “
  • 9/6/2017 – Rigel Pharmaceuticals was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 9/5/2017 – Rigel Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $5.00 price target on the stock.

Shares of Rigel Pharmaceuticals, Inc. (RIGL) opened at 3.93 on Thursday. The stock’s 50 day moving average price is $2.73 and its 200-day moving average price is $2.68. Rigel Pharmaceuticals, Inc. has a 12 month low of $1.94 and a 12 month high of $4.07. The company’s market cap is $488.86 million.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.01). Rigel Pharmaceuticals had a negative net margin of 354.14% and a negative return on equity of 105.86%. During the same period last year, the firm earned ($0.15) earnings per share. Equities research analysts expect that Rigel Pharmaceuticals, Inc. will post ($0.60) earnings per share for the current year.

Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Receive News & Ratings for Rigel Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.